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The ubiquitin-proteasome system (UPS) is a crucial protein degradation system in
eukaryotes. Herein, we will review advances in the understanding of the role of several
proteins of the UPS in Alzheimer’s disease (AD) and functional recovery after spinal
cord injury (SCI). The UPS consists of many factors that include E3 ubiquitin ligases,
ubiquitin hydrolases, ubiquitin and ubiquitin-like molecules, and the proteasome
itself. An extensive body of work links UPS dysfunction with AD pathogenesis and
progression. More recently, the UPS has been shown to have vital roles in recovery
of function after SCI. The ubiquitin hydrolase (Uch-L1) has been proposed to increase
cellular levels of mono-ubiquitin and hence to increase rates of protein turnover by the
UPS. A low Uch-L1 level has been linked with Aβ accumulation in AD and reduced
neuroregeneration after SCI. One likely mechanism for these beneficial effects of
Uch-L1 is reduced turnover of the PKA regulatory subunit and consequently, reduced
signaling via CREB. The neuron-specific F-box protein Fbx2 ubiquitinates β-secretase
thus targeting it for proteasomal degradation and reducing generation of Aβ. Both
Uch-L1 and Fbx2 improve synaptic plasticity and cognitive function in mouse AD
models. The role of Fbx2 after SCI has not been examined, but abolishing ß-secretase
reduces neuronal recovery after SCI, associated with reduced myelination. UBB+1,
which arises through a frame-shift mutation in the ubiquitin gene that adds 19 amino
acids to the C-terminus of ubiquitin, inhibits proteasomal function and is associated
with increased neurofibrillary tangles in patients with AD, Pick’s disease and Down’s
syndrome. These advances in understanding of the roles of the UPS in AD and SCI
raise new questions but, also, identify attractive and exciting targets for potential, future
therapeutic interventions.
Keywords: ubiquitin-proteasome system, Alzheimer’s disease, spinal cord injuries, beta-amyloid clearance,
neuroregeneration
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INTRODUCTION
The ubiquitin-proteasome system (UPS) is a major intracellular
protein degradation system (Schwartz and Ciechanover, 2009).
Initially, ubiquitin is activated through the ATP-dependent
formation of a high energy thioester bond between the active
site cysteine of the ubiquitin activating enzyme (E1), and the
carboxyl terminus of ubiquitin. Ubiquitin is then transferred to
ubiquitin conjugases (E2), and is finally conjugated to lysine
residues within the substrate, or to the N-terminal amino
group, by an ubiquitin (E3) ligase, which recognizes specific
motifs in the targeted protein. Additional ubiquitin molecules
are conjugated onto the first, forming a polyubiquitinated
adduct that is recognized by the 26S proteasome leading to
substrate degradation (Figure 1; Bence et al., 2001; Adams,
2003).
Dysfunction of the UPS is associated with many neurological
diseases including Alzheimer’s disease (AD), Amyotrophic
Lateral Sclerosis (ALS), neuronal degeneration, remodeling and
regeneration after spinal cord injury (SCI), Parkinson’s disease
(PD), Transmissible Spongiform Encephalopathies (TSE), and
Huntington’s disease (HD; Leigh et al., 1991; Neumann et al.,
2006). The impact of the UPS in these disorders may be
related to deficits in the clearance of misfolded proteins
leading to intracellular protein aggregation, cytotoxicity, and cell
death (Demuro et al., 2005; Schwartz and Ciechanover, 2009).
Ubiquitinated proteins are detected in oligomeric beta-amyloid
(Aβ) plaques and neurofibrillary tangles, and a mutation in the
UPS associated gene UBB+1 causes neuronal degeneration, and
has been linked to AD (van Leeuwen et al., 1998; Tan et al., 2007)
and to spatial memory impairment (van Tijn et al., 2011).
There are interesting similarities in the role of the UPS
in SCI and AD although these neurological conditions differ
in etiology, age at onset, and region of the central nervous
system (CNS) affected. AD is the most common cause of
dementia and is a degenerative disorder of the characterized
by memory loss, and neuropathologically by accumulation of
Aβ in neurofibrillary tangles. SCI is trauma whereas AD is
a degenerative disorder of older individuals. SCI results from
traumatic injury to the spinal cord that is most commonly
due to motor vehicle accidents, sports or falls, and which
results in partial or complete loss of sensation and voluntary
movement below the site of the injury. SCI is most common in
younger men although a bimodal distribution is now recognized
reflecting the growing number of new cases of SCI in the
elderly. SCI affects approximately 275,000 individuals in the
united states with approximately 12,000 new cases each year.
UPS dysfunction is closely associated with the pathological
hallmarks of AD including the accumulation of Aβ, formation
of Aβ plaques, and hyper-phosphorylation of Tau, which is
the major component of intracellular neurofibrillary tangles.
The UPS is also involved in neuronal signaling pathways that
regulate neurotransmitter release, synaptic membrane receptor
turnover and synaptic plasticity (Zhao et al., 2003; Patrick,
2006). Compelling evidence indicates that the UPS also plays
a role in the recovery from SCI (Coleman and Perry, 2002).
While the accumulation/aggregation of ubiquitinated protein is
a biomarker in the early response to SCI due to the impairment
of proteasome function (Li and Farooque, 1996; Myeku et al.,
2012), an increase in ubiquitin levels is essential for neuronal
regeneration after SCI (Schwartz and Ciechanover, 2009; Noor
et al., 2011). Furthermore, the UPS also has a role in neuronal
development, differentiation, and programming of neuro-stem
and neuroprogenitor cells. Regulation of Aβ production by the
UPS may have a role in both AD pathogenesis and recovery from
SCI. There are several excellent reviews that have discussed the
mechanisms and relationships of UPS and tau phosphorylation
in AD development (Ciechanover and Kwon, 2015; Gentier
and van Leeuwen, 2015; Kumar et al., 2015), and also many
reviews that highlight deubiquitination enzymes and the E3
ligases in the role of substrate recognition and ubiquitination.
In this review, we have focused on several recent areas of
new research: the role of ubiquitin C-terminal hydrolase L1
(Uch-L1), Ubiquitin-B+1 (UBB+1), F-box protein 2 (Fbxo2), and
aggregation-promoting chaperones (CRAM-1 and MOAG-4) in
Amyloid precursor protein (APP) and Aβ related metabolism as
well as the related signaling pathways in AD and SCI, and discuss
pressing questions in these fields of research. We also discuss
the possibility that one or more of these molecules are potential
targets for pharmaceuticals.
TARGETING Uch-L1 AND Fbx2 IN AD
Uch-L1 Regulates the CREB Signaling
Pathway in AD
UPS dysfunction slows or stops the degradation of many
proteins, including misfolded proteins, and results in protein
aggregation in the cytoplasm, nucleus and extracellular space
of neurons. Formation of inclusion bodies disrupts cell
homeostasis, axonal transport, synaptic receptor activity, and
neurotransmitter release (Ehlers, 2003; Jarome et al., 2013), and
also results in mitochondrial swelling and damage (Maharjan
et al., 2014), impaired cell differentiation, degeneration, and
neuronal death via apoptosis or necrosis (Schwartz and
Ciechanover, 2009; Kaang and Choi, 2012). In neurons,
the cyclic adenosine 3′,5′-monophosphate (cAMP)-cAMP-
dependent protein kinase (PKA)-cAMP response element-
binding protein (CREB) signaling pathway is implicated in
synaptic plasticity and cognitive function, and is regulated by
the UPS through degradation of the regulatory subunit of PKA
(Vitolo et al., 2002). The activation of PKA and the increase
of CREB phosphorylation are essential for the formation of
stable long term memory (Chain et al., 1999; Fioravante and
Byrne, 2011). This signaling pathway has been shown to be
compromised by Aβ both in vitro, using oligomeric Aβ treated
cultured neurons or brain slices, and in vivo as evidenced by
Aβ overproducing transgenic AD mouse models (Vitolo et al.,
2002; Gong et al., 2004; Smith et al., 2009). Consequently, a
decrease in PKA-pCREB levels may contribute to impairment
of synaptic plasticity and learning function in AD (Gong
et al., 2006; Atkin and Paulson, 2014). It was postulated that
compounds that enhance levels of pCREB in brain, such as
cAMP phosphodiesterases (PDE) 4, 5 inhibitors, have beneficial
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FIGURE 1 | Three steps of the ubiquitin-proteasome system (UPS) involved in substrate degradation. (A) Ubiquitin-activating enzymes (E1) form a thioester
bond with ubiquitin in a reaction that requires ATP. (B) Ubiquitin is transferred to ubiquitin conjugases with which a new, high-energy thioester bond is formed.
(C) Ubiquitin ligases (E3) provide substrate recognition and catalyze the covalent attachment of ubiquitin to the target substrate via an isopeptide bond. The
polyubiquitinated substrate is shuttled to the 26S proteasome for degradation.
effects on cognitive function (Gong et al., 2004; Navakkode et al.,
2004).
In the search for UPS regulators to modulate PKA-
pCREB levels in the brain, it was found that in the
snail Aplysia, the ubiquitin C-terminal hydrolase (Ap-Uch, a
homolog of vertebrate Uch-L1) enhances the degradation of the
polyubiquitinated R subunit of PKA (Hegde et al., 1997). Uch-
L1 is an abundant deubiquitinase (1–5% of soluble protein in
brain) that is expressed in neurons, testis and ovaries (Wilkinson
et al., 1989; Osaka et al., 2003). Uch-L1 exists as both a soluble
form in the cytosol, which accounts for 70–80% of Uch-L1
protein, and a membrane-bound form (Bishop et al., 2014).
While the reduction of cytosolic Uch-L1 may be linked to the
pathogenesis of AD by contributing to abnormal tau metabolism
and Aβ plaque, membrane bound Uch-L1 may be associated
with α-synuclein dysfunction in PD (Liu et al., 2009; Chen et al.,
2013). Uch-L1 is a highly conserved protein with a catalytic Cys
at residue 100 and active site His at residues 107 and 181. The
major proposed functions of Uch-L1 are: (1) cleavage of α- and
ε-amino acid linked ubiquitin molecules from polyubiquitin
chains or polyubiquitinated proteins, respectively (Wilkinson
et al., 1989; Larsen et al., 1998) to provide a pool of mono-
ubiquitin and regulate ubiquitin homeostasis; and (2) directly
binding to mono-ubiquitin to mask mono-ubiquitin activating
sites such as Glu64, Phe4, Leu8 and Leu43 (Nakatsu et al.,
2000; Shih et al., 2000) to avoid the mono-ubiquitination of
substrates that would otherwise shunt them to the endosomal-
lysosome pathway to be degraded (Osaka et al., 2003). Uch-L1
C-terminal hydrolase activity can be measured in vitro by an
enzyme assay using the fluorogenic substrate Ub-AMC, and its
activity can be effectively inhibited by the specific inhibitor LDN-
57444 (Wilkinson et al., 1989; Gong et al., 2006). Interestingly,
Uch-L1 also acts as an ubiquitin ligase and through such
activity may have links with PD (Liu et al., 2002, 2006). Studies
in AD brains have shown that Uch-L1 deficits are linked
to the accumulation of Aβ in the ascending gracile tract as
demonstrated by a mouse model of gracile axonal dystrophy
(GAD; Osaka et al., 2003), and there is an association between
Uch-L1 gene S18Y polymorphisms and sporadic AD (Xue and
Jia, 2006; Zetterberg et al., 2010). Uch-L1 levels decrease in
postmortem brains of AD patients and in AD transgenic mouse
models, coinciding with the accumulation of ubiquitinated
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protein in Aβ plaques and neurofibrillary tangles (Gong et al.,
2006; Zetterberg et al., 2010). Similar to Ap-Uch, human Uch-L1
increases the ubiquitination of the R (regulatory) subunit of
PKA in the neuronal cytoplasm by providing mono-ubiquitin to
promote proteasomal degradation of the R subunit, thus freeing
the PKA catalytic subunit to phosphorylate CREB in the brain
(Vitolo et al., 2002; Poon et al., 2013). Uch-L1 also modulates
the turnover of the glutamate receptors NMDAR and AMPAR,
and has effects on neurotransmitter release (Cartier et al.,
2009). Enhancing Uch-L1 expression in the brain could have
beneficial effects on synaptic function and improve cognition
in AD. This premise is supported by studies showing that
overexpressing Uch-L1 or pharmacologically enhancing Uch-L1
activity, improves long term potentiation (LTP) and cognition
in AD transgenic mouse models (Gong et al., 2006), whereas
knocking out Uch-L1 or pharmacologically inhibiting Uch-L1
causes a decline in cognition (Kurihara et al., 2001; Gong
et al., 2006; Chen et al., 2010; Figure 2). This suggests that
factors regulating Uch-L1 activity may be potential targets
for AD therapeutics. However, more studies are needed to
uncover (1) what other signaling pathways that are regulated
by Uch-L1 and (2) the effect of such regulatory influences on
neuronal function. For example, it remains to be determined
how Uch-L1 is involved in the activation of the transcription
factor of nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-κB) or in tumor necrosis factor (TNF)-induced
necroptosis.
Uch-L1/UBB+ are involved in the
Regulation of Aβ Production
Earlier studies failed to demonstrate a significant effect of
Uch-L1 manipulations on APP processing and Aβ production
in the brain (Gong et al., 2006). However, recent publications
show that Uch-L1 is indeed involved in the degradation of
APP and beta-site APP cleaving enzyme 1 (BACE1), one of
the two essential enzymes cleaving APP and producing Aβ
in brain. Overexpressing Uch-L1 reduces BACE1 activity and
Aβ levels, whereas Uch-L1 null mice exhibit increased number
of Aβ plaques and neurofibrillary tangles, thus displaying an
inverse relationship with Uch-L1 levels (Choi et al., 2004;
Qing et al., 2004). The discrepancy in the results of various
FIGURE 2 | Scheme depicting how Uch-L1 affects PKA activity, enhances pCREB levels, and improves synaptic plasticity (adapted from Gong et al.,
2006). Aβ inhibits adenylate cyclase (AC) and proteasomal degradation of the RIIa subunit (R), resulting in its accumulation and a shift of the equilibrium in the PKA
complex toward the inactive tetramer. As a consequence, the transcription factor CREB cannot be phosphorylated and initiates transcription. Uch-L1 re-establishes
normal proteasomal activity leading to normal levels of RIIa subunit which in turn phosphorylates CREB, thus rescuing synaptic function.
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trials regarding the effect of Uch-L1 on Aβ may be due to
different dosages and durations of the Uch-L1 treatment in the
experimental mice. The mechanism by which Uch-L1 reduces
Aβ accumulation and toxicity is unclear. It is postulated that
it could be linked to increased APP degradation in Golgi
or ER, thus reducing APP levels available to be cleaved by
BACE1. Uch-L1 may also affect APP axonal translocation
to synaptic terminals, thus reducing Aβ induced neuronal
toxicity at the synapse. The latter is consistent with Uch-L1
improving synaptic plasticity in AD mouse models. Thus, there
may be multiple pathological mechanisms contribute to the
cognitive dysfunction and development of AD. Moreover, drugs
may improve cognitive function without altering Aβ levels,
which is in agreement with reports suggesting that the clinical
phenotype is not always closely related with the Aβ plaque
numbers or load in postmortem AD brains (Aizenstein et al.,
2008).
A frameshift mutation in the ubB (ubiquitin) gene (UBB+1)
selectively expressed in brain was associated with increases
in neurofibrillary tangles and plaques in AD, Pick’s disease
and Down’s syndrome patients, but was not found in the
healthy young population, which suggests a link between the
UPS and AD pathogenesis (van Leeuwen et al., 1998, 2006).
The polyubiquitin chain, which is essential for degradation
of most substrates by the 26S proteasome, is formed through
isopeptide bonds between the carboxyl terminus of Gly76 of
one ubiquitin and the amino group of the lysine residues
at positions 48 (K48) of another ubiquitin molecule (Chau
et al., 1989). UBB+1 is a result of a dinucleotide deletion
during transcription causing frameshift that replaces the
glycine at the C-terminus of wild-type ubiquitin with a 19
residue insert (UBB+). The precise mechanism by which
UBB+1 influences protein degradation is not clear. While
K48 is preserved, UBB+1 cannot form polyubiquitin chains
because of the absence of a C-terminal Gly; overexpression of
UBB+1 results aggregation of ubiquitinated protein in UBB+1
overexpressing cells (van Tijn et al., 2007) and mice (Irmler
et al., 2012). Moreover, UBB+1 conjugated proteins are toxic
and directly inhibit 26 proteasome activity, causing aggregation
of ubiquitinated protein (Ciechanover and Kwon, 2015). This
aberrant UBB+1 has been linked with the accumulation of
Aβ and tau in the brain in AD in both post-mortem brains
from patients and transgenic mice (Lindsten et al., 2002;
Shabek et al., 2009; Dennissen et al., 2010). Studies with AD
mouse models showed that knockdown of UBB+1 decreases
the steady-state levels of APP, as well as the production
of sAPPα, APP C-terminal fragments (CTF), C83 and APP
intracellular domain (AICD; Gentier and van Leeuwen, 2015).
Conversely, overexpression of UBB+1 increased the levels of
APP and Aβ in cultured neuron cells, possibly by reducing
the degradation of APP by proteasomes, thus shifting APP
into an Aβ production pathway (Massey et al., 2004; Hiltunen
et al., 2006; Viswanathan et al., 2011). Therefore, UBB+1 is
involved in both secretase-dependent and independent pathways
for Aβ generation and this could be a reasonable explanation
as to why UBB+ conjugated protein aggregation has been
found to be associated with Aβ plaques in transgenic UBB+1
AD brain (van Leeuwen et al., 2006; Zhang et al., 2007; El
Ayadi et al., 2012). Since Uch-L1 and UBB+1 exert opposite
effects on Aβ processing, metabolism and polyubiquitin chain
formation, pharmacological modulation of UBB+1 or Uch-L1
levels in the brain may be a potential therapeutic strategy
for AD.
Because Uch-L1 has been found play a role in synaptic
function and BACE1 degradation (see below), it will be
interesting to know whether UBB+1 has the opposite effect on
synaptic plasticity in the AD brain, what signaling pathways are
involved, and if UBB+1 also linked BACE1 degradation. Further
studies in animal models produced by crossing the UBB+1/Uch-
L1 with AD mouse models such as APP or APP/S1 are needed.
These studies will provide the basis for screening compounds
affecting Uch-L1 and UBB+1 levels that could improve synaptic
and cognitive function in AD patients.
Role of the E3 Ligase Fbox2 in Aβ
Processing and Synaptic Function
The UPS is postulated to be involved in the degradation of
APP and the attenuation of Aβ accumulation in the brain
(Kang et al., 2010; Zhang et al., 2012). Several E3 ligases have
been reported to be linked with APP and Aβ processing such
as HRDI (Kaneko et al., 2010), the C-terminus of HSP70
interacting protein (CHIP; Kumar et al., 2007) and FBXW7
(Li et al., 2002) which is possibly regulated through the ER
associated protein degradation pathway (ERAD). Reductions
of E3 ligase function may cause APP accumulation and Aβ
generation, whereas, overexpression of these E3 ligases may
result in decreased level of Aβ in in vitro models. This field
has been recently reviewed in depth (Atkin and Paulson, 2014).
Here, we will focus our discussion on a newly identified,
neuron-specific F-box protein, Fbx2. Fbx2 was found to
contribute to the rapid elimination of neuron-specific membrane
proteins, including neurotransmitter receptors and postsynaptic
scaffolding proteins, by promoting their ubiquitination (Yoshida
et al., 2003; Lin and Man, 2013; Atkin et al., 2014). Fbx2 is
a member of the SCF-Fbx2-E3 ligase complex. Through its
FBA (F-box associated) domain, Fbx2 attaches polyubiquitin
chains to high-mannose N-linked glycosylated substrates, thus
targeting them for proteasomal degradation via the ERAD
pathway (Nelson et al., 2006). Recently, we found that Fbx2
specifically recognizes and binds BACE1 through its FBA
domain, thus increasing BACE1 ubiquitination (Gong et al.,
2010). Normally, Fbx2 is expressed in various intracellular
organelles in brain neurons, and BACE1 is co-localized with
Fbx2 mainly in the early endosome and ER (Ko and Puglielli,
2009). Moreover, APP, which is cleaved by BACE as a critical
step in the production of Aβ in neurons, is located in
the endosome and Golgi complex, and is co-localized with
BACE1. During metabolic stresses such as increased oxidative
phosphorylation or changes in cytoplasmic homeostasis that
induce ER stress, the UPS will be compromised, which would
most likely result in a reduction in BACE1 degradation by the
UPS and lysosomes. The increased levels of BACE1 therefore are
associated with an increase in APP cleavage and overproduction
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of Aβ (O’Connor et al., 2008; Gong et al., 2010; Singh and Pati,
2015).
We established that Fbx2 overexpression in primary neurons
derived from Tg2576 transgenic mice, a well characterized AD
mouse model (Hsiao et al., 1995), significantly promoted BACE1
degradation and reduced Aβ production. Not surprisingly, Fbx2
overexpression regulated LTP in the hippocampus. In our in vivo
studies with Tg2576 mice, we found that stereotactic delivery
of adenoviral-Fbx2 to the brain significantly increased Fbx2
expression and decreased synaptic deficits coinciding with a
reduction of BACE1, which is essential for Aβ formation (Gong
et al., 2010, 2013b). Moreover, we and others demonstrated
that in addition to BACE1, the SCF-Fbx2-E3 ligase is involved
in binding and ubiquitination of the NMDA and AMPA
receptors at the synaptic membrane, affecting receptor turnover
during neuronal activation (Kato et al., 2005; Gong et al.,
2010). Recently, it was reported that APP is also one of
the substrates for Fbx2 ligase (Atkin et al., 2014). APP
levels are decreased in the Fbx2 overexpressing cells and
increased in hippocampal neurons of Fbx2 knockout mice.
The increase in total APP and decrease in surface membrane-
bounded APP coincides with higher levels of Aβ in the Fbx2
knockout mice due to subsequent cleavage by β- and γ-
secretases.
In summary, there may be two major mechanisms by which
Fbx2 regulates synaptic plasticity in AD mouse models: one
is through a direct regulation of synaptic neurotransmitter
release and receptor turnover; the second may be due to
stimulation of the degradation of BACE1/APP to reduce Aβ
levels in the brain. Therefore, the Fbx2 E3 ligase could be
another potential target for AD treatment. For example, we
previously reported that nicotinamide riboside, a potent inducer
of Fbx2 expression in neurons, significantly increased the
binding of BACE1 to ubiquitin, enhanced BACE1 degradation
by proteasome, and thus reduced Aβ toxicity (Gong et al.,
2013a). Thus, it would be meaningful to screen compounds
that have similar function as nicotinamide that able to boost
Fbx2 expression/function in neuronal cells, and then apply these
compounds in animal models to test their in vivo functions and
effects.
Functional Links between the
Ubiquitin-Proteasome System and
Mitochondrial Impairment in AD
It is clear that the function of the UPS is perturbed in AD
(Ding et al., 2006; Oddo, 2008; Riederer et al., 2011). Defective
proteasome activity is detected in the early phase of AD along
with synaptic dysfunction, and in late AD stages is associated
with the accumulation and aggregation of ubiquitinated (Ub)-
proteins which precedes tangle formation (García Gil et al., 2001;
Upadhya and Hegde, 2007; Oddo, 2008; Bedford et al., 2009).
Mitochondrial impairment is also involved in AD (Eckert et al.,
2011; Stranahan and Mattson, 2012; Selfridge et al., 2013). In
particular, reduced brain glucose metabolism is detected early in
AD patients and is implicated in the initiation and progression of
AD pathology (Mosconi et al., 2008). In neurons, even a modest
restriction of ATP production by mitochondria seems to far
outweigh the effects of reactive oxygen species (ROS; Nicholls,
2008). We will discuss the functional link between UPS and
mitochondrial dysfunction, and its impact on AD.
The UPS plays a critical role in the pathogenesis of
AD (Riederer et al., 2011). Proteasome impairment could be
an upstream event leading to the AD pathogenic cascade.
Supporting this notion, we showed that in rat cerebral cortical
cultures, short term (4–8 h) proteasome inhibition results in
the accumulation of soluble Ub-proteins without significant loss
in neuronal viability (Metcalfe et al., 2012). However, longer
proteasome inhibition (16–24 h) induces a rise in Ub-protein
aggregates, coinciding with caspase-activation, caspase-cleavage
of the microtubule associated protein Tau to an aggregation
prone form, and neuronal death (Metcalfe et al., 2012). The
identity of the factors that induce the transition from soluble to
aggregated Ub-proteins is poorly defined. Recent studies with
the nematode C. elegans, revealed a novel protein known as
‘‘cytotoxicity-related aggregation meditaor-1’’ or CRAM-1 that
acts as an aggregation modulator (Ayyadevara et al., 2015).
Glutamine/asparagine-rich proteins, which favor hydrophobic
interactions with random-coiled domains, seem to be the most
susceptible to aggregation (Ayyadevara et al., 2015). CRAM-1 is
a highly disordered protein lacking defined protein motifs, and
has the ability to sequester unstructured or unfolded proteins.
CRAM-1 binds to the polyubiquitin tags of these proteins
and blocks their proteasomal degradation and/or targeting to
autophagy. This crude sequestration mechanism ultimately leads
to an unsustainable aggregate burden (Ayyadevara et al., 2015).
Another C. elegans protein that plays a similar sequestration
role, but functions independent of ubiquitin binding, isMOAG-4
(modifier of aggregation 4) which is homologous to human
SERF1 (van Ham et al., 2010). MOAG-4/SERF1 is a specialized
and autonomous amyloid factor that promotes aggregation
of a broad range of amyloidogenic proteins but is inactive
against non-amyloid aggregation (Falsone et al., 2012). Both
of these primitive chaperones, CRAM-1 and MOAG/SERF1,
impair survival and could act as non-competitive inhibitors of
the proteasome in an age-dependent manner relevant to AD
(Ayyadevara et al., 2015).
The high levels of oxidized proteins detected in the brains
of AD patients are an indirect indication of proteasome
impairment, since this proteolytic complex degrades the majority
of oxidatively modified proteins (Grune et al., 2004). Impaired
clearance of oxidatively modified proteins can cause their
aggregation and directly promote the progression of the
neurodegenerative process (Grune et al., 2004). Moreover, the
accumulation and aggregation of Ub-proteins detected in most
neurodegenerative disorders including AD, is also a sign of
UPS dysfunction, since this pathway degrades Ub-proteins
(Alves-Rodrigues et al., 1998). Impairment in proteolysis
mediated by the UPS has profound ramifications for neuronal
viability. It leads to the accumulation of modified, potentially
toxic proteins in neurons and can cause neuronal injury or
premature neuronal death by apoptosis or necrosis (Dasuri
et al., 2013). While it is accepted that proteasome function
decreases in AD, the question remains why is there a decline
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in regulated protein degradation by the UPS under these
conditions.
One of the emerging factors associated with UPS impairment
is mitochondrial dysfunction (Livnat-Levanon and Glickman,
2011). A mechanism by which mitochondrial dysfunction
contributes to aging and neurodegeneration is via a net increase
in the production of ROS (Zhu et al., 2013). Oxidative
stress induced by ROS alters the structure of cellular proteins
(Stadtman and Berlett, 1998), which, if not repaired, must
be removed by proteolysis to prevent their accumulation and
aggregation. Although one of themajor roles of the proteasome is
to degrade oxidatively modified proteins, whether ubiquitination
is required remains elusive (Shang and Taylor, 2011). This is an
interesting issue since there is ample evidence that neural tissues
are especially vulnerable to oxidative stress, which is linked to
AD pathogenesis (Eckert et al., 2011). Neurons exhibit a higher
sensitivity to proteasome inhibition than astrocytes, mostly
because they exhibit increased levels of oxidized proteins (Dasuri
et al., 2010). Interestingly, cysteine deubiquitinases are proposed
to be highly sensitive redox biosensors that become inactive
and promote a quick response independent of protein synthesis
or protein modification (Cotto-Rios et al., 2012; Eletr and
Wilkinson, 2014). Furthermore, K63-linked polyubiquitination
was proposed to be a new modulator of the oxidative stress
response induced by peroxides (Silva et al., 2015). In S. cerevisiae,
three different components of the UPS, the Ub-conjugase Rad6,
the Ub-ligase Bre1, and the deubiquitinase Ubp2, were shown
to work in concert to regulate K63-linked polyubiquitination of
various ribosomal proteins (Silva et al., 2015). Disrupting K63-
linked polyubiquitination under peroxide-induced oxidative
stress destabilizes polysomes, impairs protein synthesis, and
increases the vulnerability of cells to stress (Silva et al., 2015).
Thus K63-linked polyubiquitination seems to play a new role
as a redox-regulator of protein translation by ribosomes, while
K48-linked polyubiquitination regulates protein degradation by
proteasomes.
Another deleterious mechanism associated with
mitochondrial dysfunction is the limitation in ATP production
that can cause an energy crisis in neurons (Nicholls, 2008).
Degradation of proteins by the 26S proteasome is highly
dependent on ATP binding and hydrolysis (Liu et al., 2006).
We investigated the effects of mitochondrial impairment in rat
cerebral cortical neurons treated with oligomycin, antimycin,
and rotenone, all of which inhibit different elements of the
mitochondrial electron transport chain and thus cause a
significant decline in ATP (Huang et al., 2013). Our study
revealed that a decline in ATP leads to multiple adverse effects:
(1) A shutdown of the ubiquitination cascade occurred and was
caused by inhibition of ubiquitin adenylation carried-out in an
ATP-dependent manner by the E1 ubiquitin activating enzyme;
(2) Disassembly of the 26S proteasome was observed and was
triggered in part by the selective cleavage of Rpn10 by calpain,
which is activated under conditions of ATP deficit. No other
proteasome subunit tested was cleaved by calpain. Rpn10 could
act as a 26S proteasome gatekeeper sensitive to ATP deficits;
(3) There was, accordingly, an increase in the activity of the
20S proteasome, which in concert with immunoproteasomes is
postulated to degrade oxidatively modified proteins (Grune et al.,
2004); and (4) Cleavage of Tau in a calpain-dependent manner
was found, leading to a ∼17 kDa fragment which is presumed
to be toxic (Garg et al., 2011). These data are highly significant
to AD because: (1) mitochondrial dysfunction (Selfridge et al.,
2013) and calpain-activation are linked to AD (Saito et al.,
1993; Ferreira and Bigio, 2011); and (2) calpain-dependent Tau
fragments are detected in the brains of AD patients (Ferreira and
Bigio, 2011; Garg et al., 2011). In conclusion, both deleterious
consequences of mitochondrial impairment, i.e., restricted
ATP generating capacity and ROS production, impair UPS-
dependent proteolysis in neurons and are highly relevant to the
pathogenesis of AD.
Not only are mitochondria associated with UPS function
in regards to ATP production and the generation of ROS, the
UPS is also linked to mitochondrial function, as recent studies
revealed that the UPS degrades mitochondrial proteins and thus
contributes to mitochondrial quality control (Taylor and Rutter,
2011). Mitochondrial proteins that are UPS substrates include:
(1) damaged and/or misfolded nuclear-encoded proteins that
are destined for import into the mitochondria; (2) defective
proteins at the outer mitochondrial membrane (OMM) extracted
by p97 and delivered to the proteasome; and (3) non-OMM
proteins, although the mechanistic details of how these proteins
in the inner compartments retrotranslocate to the OMM remain
poorly defined (Farhoud et al., 2012). UPS impairment impacts
several aspects of mitochondrial function that include: (1)
mitochondrial dynamics (Carlucci et al., 2008) via the scaffold
protein AKAP121; (2) mitochondrial biogenesis (Farhoud et al.,
2012) via Peroxisome proliferator-activated receptor-gamma
coactivator (PGC-1α); and (3) mitochondrial fission via Drp1
(Kanamaru et al., 2012). These factors are turned over by the
UPS, and are perturbed in AD by either reduced expression,
mis-localization, or an interaction with Tau (Carlucci et al., 2008;
Trausch-Azar et al., 2010; Merrill et al., 2011; Manczak and
Reddy, 2012; Sheng and Cai, 2012; Sheng et al., 2012).
In conclusion, it is clear that there is a mutual dependance
between the UPS and mitochondria (Livnat-Levanon and
Glickman, 2011). New discoveries regarding the functional links
between UPS and mitochondrial impairment and their roles in
overall neuronal homeostasis could lead to novel and successful
therapeutic approaches for AD (Huang and Figueiredo-Pereira,
2010). Thus, future studies are needed to better understand how
PGC-1α promotes the mitochondrial biogenesis and how the
proteasome affects the inner compartments of mitochondrial
retrotranslocation to the OMM, and more practically, to test
whether stabilization of K63-linked polyubiquitination is able to
resist the oxidative stress induced impairment of mitochondrial
function in animal models.
THE UPS IN SPINAL CORD INJURY
Ubiquitin and Uch-L1 Participate in
Neuronal Regeneration After SCI
SCI most commonly results from traumatic injuries to the spinal
cord. The initial mechanical disruption of white matter tracts is
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rapidly exacerbated by multiple secondary sequelae that include
ischemia, inward calcium flux, infiltration with inflammatory
cells and liberation of high levels of ROS which evolve over
time to produce a chronic state of inflammation. The acute and
chronic production of ROS in the injured spinal cord may be
expected to have multiple deleterious effects. ROS are reported
to cause oxidation of the catalytic cysteine residue at the active
site of E1 and E2 enzymes and promote the formation of E1/E2-
containing disulfide complexes, which prevents these enzymes
from catalyzing ubiquitination [note: this would decrease levels
of ubiquitin conjugates] (Hunter, 2007). Severe oxidative stress
also impairs proteasome activity thereby increasing ubiquitin
conjugates (Shang and Taylor, 2011). Consistent with the notion
that proteasome function is impaired after SCI, ubiquitinated
proteins have been demonstrated to accumulate in human spinal
cord axons in after SCI (Ahlgren et al., 1996). Ubiquitinated
protein aggregates have also been found in neurons of dorsal
root ganglia and spinal cord gray matter of rats after spinal cord
compression (Li and Farooque, 1996). Selective motor neuron
death, induced by transient spinal cord ischemia associated with
trauma or surgery, was found to correlate with redistribution
of Aβ, ubiquitin, Uch-L1 and the formation of aggregates of
proteins in neuronal cytoplasm and nuclei (Yamauchi et al., 2007;
Myeku et al., 2012). The increase of ubiquitin and Uch-L1 was
observed at the early stage of re-perfusion, after the 15 min
spinal cord ischemia, and had resolved by 6 h after re-perfusion
in experimental animal models. These findings suggest a strong
relationship between vulnerability of motor neurons and the
ubiquitin-mediated stress response (Yamauchi et al., 2008).
A critical area of research is understanding mechanisms
of neuronal death after SCI and identification of strategies to
increase numbers of neurons that survive after the trauma, or
so called neuroprotection. Even if damage to the descending
and ascending axons in white matter can not be prevented,
interneurons present in gray matter may provide a means
to rewire spinal cord circuits to restore some connectivity
between the cortex and periphery (Courtine et al., 2008). Several
lines of evidence link ubiquitin, Uch-L1 and E3 ubiquitin
ligases to survival of such interneurons. Specifically, spinal cord
interneurons with increased ubiquitin and Uch-L1 expression
have been reported to have greater cell survival after SCI (Noor
et al., 2013). Similarly, ubiquitin and Uch-L1 up-regulation has
also been observed in complete spinal cord transection (Fry
et al., 2003; Lane et al., 2007). In addition, vulnerability of
motor neurons of the spinal cord can be partially attributed to
differences in ubiquitin-mediated stress responses after transient
ischemia (Sakurai et al., 1998; Yamauchi et al., 2008). Therefore, a
failure to upregulate ubiquitin in motor neurons could represent
a great disadvantage for motor neuron recovery (Mengesdorf
et al., 2002). Moreover, the ubiquitin E3 ligase ZNRF1 (zinc
and ring finger 1) has been demonstrated to be associated
with Wallerian degeneration after SCI (Araki and Milbrandt,
2003). Thus the significant changes in ubiquitin expression and
cellular distribution in response to SCI, and its effects on the
neuronal regeneration and myelination, suggest that the UPS
could have a significant role in recovery from SCI caused by
ischemia.
Once the acute inflammatory response to SCI has
resolved, spinal cord neurons engage in a process of rewiring
(neuroplasticity) and in efforts to extend new axons across the
injured region (neuroregeneration). Studies in Monodelphis
domestica andmice suggest a linkage between neuroregeneration
and expression levels of components of the UPS, although the
underlying mechanisms are poorly understood. For example,
following spinal cord transection in Monodelphis domestica,
axonal regeneration and regrowth of neuronal tissue was
found at the injury site in animals injured at 7 days after birth
(P7), which was associated with upregulation of ubiquitin
mRNA and protein expression. However if injury occurred at
postnatal 28 day (p28), little or no upregulation in ubiquitin
expression occurred and no neuronal regeneration was observed
(Ji et al., 2008; Yan et al., 2010; Noor et al., 2013). The levels
of mono-ubiquitin were decreased at sites both caudal and
rostral to the SCI injury site in aged animals, which also have
reduced neuroregenerative capabilities; the magnitude of the
decrease was found to be age-related. The reduction in ubiquitin
levels may also be associated with involvement of ubiquitin
in multiple functions and substrates in an organism outside
of the proteasome system such as receptor internalization
and modifications to chromatin structure (Noor et al., 2011).
Moreover, the distribution of ubiquitin in response to the SCI
also plays a role in the recovery of the spinal cord. For example,
in motor neurons or interneurons of the ventral horn, ubiquitin
is significantly increased in the cytosol after injury of postnatal 7
day (p7) mice which demonstrate significant neuroregenerative
capabilities. By contrast, in mature mice, where the capacity of
neuron regeneration is lost, there is minimal change in ubiquitin
levels in the cytosol of ventral horn neurons, in which ubiquitin
was primarily localized to the nuclei (Noor et al., 2011, 2013).
These findings suggest that the growth inhibitory or stimulatory
factors that explain the difference in neuroregenerative capacity
between young and old mice regulate ubiquitin expression and
localization and support the view that certain levels of ubiquitin
in injured neurons are essential for neuron regeneration. An
open question is whether certain deubiquitinating enzymes such
as Uch-L1 could be beneficial for the SCI. It is notable therefore
that Uch-L1 has been reported to promote neurogenesis and
regulate differentiation of neuronal progenitors and has been
proposed as a potential stem-cell based therapeutic target in the
SCI (Sakurai et al., 2006; Naujokat, 2009).
Several neuroprotective drugs have been shown to reduce
accumulation of aggregated, ubiquitinated proteins. Elevation of
cAMP in rat spinal cord neurons by rolipram, a PDE4 inhibitor,
or dibutyryl-cAMP, is neuroprotective and is associated with the
increase in proteasome function by enhancing 19S regulatory
particle ATPase 6 (Rpt6), and β5 subunit of the central beta-rings
of 20S proteasome activity and other components of the UPS
including UBB and the E3 ligase CHIP, resulting in a decrease in
aggregation of ubiquitinated protein in SCI (Myeku et al., 2012).
Since Uch-L1 enhances the down-stream signaling pathways of
cAMP by acting on PKA, this provides another rationale for the
targeting of Uch-L1 in SCI treatment.
In summary, the UPS is impaired after SCI, and ubiquitin
levels are positively associated with neuroregeneration. While
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it is logical to assume that elevation of Uch-L1 levels is
beneficial after SCI, this possibility has not been tested. Further
animal studies are needed in SCI models to determine if the
overexpression of ubiquitin or Uch-L1 can lead to resistance to
neural injury or promote neuroregeneration or neuroplasticity
with benefits to functional recovery.
The Role of Proteasome After SCI
Dysfunction of the proteasome may explain or contribute to
the accumulation of ubiquitinated proteins after SCI (Myeku
et al., 2012). However, the role of the proteasome in neuronal
regeneration is controversial and likely complex. It has been
found that treatment with proteasome inhibitors such as MG132
or lactacystin induces secondary axotomy of stretch-injured
axons 72 h after the injury (Du et al., 2008), and arrests neurite
outgrowth in primary cultured neurons (Laser et al., 2003). The
axonal stretch model replicates the mechanical forces acting on
brain or spinal cord following traumatic brain injury (TBI) or
SCI (Staal et al., 2007). Of relevance to traumatically induced SCI,
motor neurons are also more vulnerable to proteasome inhibitor
induced neurotoxicity, which includes apoptotic nuclear changes
and mitochondrial dysfunction (Kikuchi et al., 2002). In a
rat SCI model, cAMP induced PKA activation reduced the
accumulation of ubiquitinated protein that was caused by
proteasome inhibition in the spinal cord, thus demonstrating
a potential therapeutic approach in the prevention of neuronal
damage after SCI (Moore and Kennedy, 2006; Myeku et al.,
2012), and raising the possibility that Uch-L1 and PDE4
inhibitors may be beneficial after an SCI.
On the other hand, the drug bortezomib, a 26S proteasome
inhibitor currently used in treatment of multiple myeloma, was
found to be effective in reducing brain ischemia size in clinical
studies (Shah and Di Napoli, 2007) by increasing ubiquitin
expression in the infarct. One might posit that treatment
of bortezomib could also be beneficial after SCI to preserve
motor neurons and to improve neuronal function (Henninger
et al., 2006). Furthermore, following nerve transection, MG132,
a peptide aldehyde inhibitor of the proteasome as well as
multiple cysteine and serine proteases, delays the onset of
Wallerian degeneration (Zhai et al., 2003). Similar to the
immunohistological studies, microarray analysis showed that
inhibition of the proteasome may have both neuroprotective
and pro-apoptotic response in primary neuron cells through
upregulation of neuroprotective heat-shock proteins (HSPs;
Yew et al., 2005), of which the main subtype expressed
in motor neurons of spinal cord are Hsc70 and Hsp27
(Chen and Brown, 2007). Of interest, the induction of Hsc70
by proteasome inhibitors prevents neuregulin-induced motor
nerve demyelination and improves nerve conductance; these
changes may be related to the clearance of c-Jun (Li et al.,
2012). However, proteasome inhibition activates antioxidant and
HSP signaling pathways, which may result in neuroprotection
early after SCI and an apoptotic response at later time
points (Yew et al., 2005; Yang et al., 2006). The effects of
proteasome inhibitors are thus complex, and likely depend
on specificity of the inhibitor used and cell type, but also
may be influenced by duration and timing relative to the
initial spinal cord trauma. Additionally, proteasomes participate
in myriad cellular processes in addition to housekeeping
functions such as disposal of damaged proteins. Differences
in results of studies with proteasome inhibitors may reflect
the relative activation state of one or more signaling pathways
regulated by proteasomes, or of expression levels of E3
ligases or other components of ubiquitin machinery. Such
differences could explain, in part the divergent and at times
apparently contradictory findings with proteasome inhibitors.
Thus, further studies in animal models of SCI are needed
to explore the role of proteasomes in neuroprotection and
neuroregeneration and to define the timing of administration
of proteasome inhibitors in the protection of spinal neuron
recovery.
The Role of Ubiquitin Ligases, APP and Aβ
in Recovery After SCI
As noted above, the UPS plays critical roles in modulating
levels of APP and Aβ. Understanding of the role of Fbox2
or other E3 ubiquitin ligases in neuroregeneration or injury
to spinal cord neurons after SCI is limited to extrapolations
from our understanding of the role of these factors in Aβ
metabolism and AD pathogenesis outlined above. There is some
understanding of relationships between APP, Aβ and outcomes
after SCI which allows greater understanding of how E3 ubiquitin
ligases might be expected to influence neuroprotection or
neuroregeneration after SCI. APP is carried along the axon
by fast axonal transport. It exists in both pre- and post-
synaptic sites and has a role in synaptic function and axonal
protein transport. Generation, processing and resultant levels of
APP have been identified to be very sensitive to CNS insults
and have been extensively used as a biomarker of traumatic
axonal injury. Levels of APP immunostaining provide a gold-
standard for clinical identification of diffuse axonal injury
both in brain and SCI (Blumbergs et al., 1995; Nashmi and
Fehlings, 2001). Experimental sciatic nerve axotomy showed an
axonal accumulation of Aβ and promotion of the pathological
formation of Aβ plaques in the motor neurons in gray matter
and the glial cells present in white and gray matter of the
spinal cord, which may be a reactive response (Ahlgren et al.,
1996; Rose and Odlozinski, 1998). However, inhibition of Aβ
accumulation by inhibiting APP-γ-secretase and BACE1 was
found to reduce the recovery after SCI indicating that Aβ may
also have neuroprotective role after SCI (Ahlgren et al., 1996;
Rose and Odlozinski, 1998; Pajoohesh-Ganji et al., 2014). At
1 day after SCI, accumulation of APP and Aβ, the loss of the
cytoskeletal proteins such as microtubule associated protein-
2 (MAP-2), and axonal demyelination have been found both
within and away from injury epicenter (Li et al., 1995; Huang
et al., 2007). Such findings suggest that both the initial injury
and subsequent secondary injury caused by the activation of
cascades which spread the injury away from the trauma site are
involved in the above pathological changes. The accumulation
of APP in traumatized axons at the epicenter of the injury, and
also rostral and caudal to it, correlates with loss of motor neuron
function, further demonstrating the crucial link between APP
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and the SCI. These findings implicate impairment of both fast
anterograde and retrograde axonal transport (Medana and Esiri,
2003; Ward et al., 2014), which causes an accumulation of APP,
other axonal transport proteins, intracellular components such
as lysosomes, neurotrophin, mitochondria and synaptophysin-
carrying vesicles. Transport of these components to synapses
is essential for normal neuronal function and survival (Lazarov
et al., 2007) and could be Aβ independent (Stokin et al.,
2008). On the other hand, the build-up of APP in axons
and at synapses could cause rapid local increases in Aβ
levels following the increased cleavage of APP by γ- and β-
secretase. The increased Aβ further impairs axonal transport
causing axonal swelling due to damage to axonal microtubules.
Similar to the reported toxicity of Aβ in brain, accumulation
of Aβ in spinal cord neurons disrupts intracellular calcium
homeostasis, impairs mitochondrial function, and results in
abnormal regulation of synaptic receptors and ion channels (Pike
et al., 1993). It also induces the release of cytokines causing
neuronal inflammation and defective endo-lysosomal trafficking
(Pimplikar et al., 2010), altered intracellular signaling cascades,
or impaired neurotransmitter release thereby contributing to
synaptic dysfunction (Tang-Schomer et al., 2010). Thus, drugs
regulating ubiquitin expression after spinal injury could have
the potential to spare neurons from injury by minimizing Aβ
accumulation (Yokobori et al., 2015).
In summary, Aβ accumulation is an early response after
SCI, and its accumulation affects neuronal recovery via similar
mechanisms to those involved in AD, such as impairing
axonal transport, activating cytokine induced inflammation and
impairing neurotransmitter release in spinal cord neurons.
Further studies are needed to define which signaling pathway
is involved in Aβ induced neuronal dysfunction, if the sensory
neurons and motor neurons are shared same mechanisms, and
the role of the UPS in the regulation of Aβ accumulation in SCI.
Role of BACE1 After SCI
Increased accumulation of APP and Aβ have been reported
in axons in white matter about 1 mm from the lesion site
FIGURE 3 | Working hypothesis as to how Fbx2 facilitates beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) degradation. In the
Alzheimer’s disease (AD) brain, BACE1 is essential to cleave amyloid precursor protein (APP) to generate Aβ. Fbx2 binds BACE1 through an F-box domain and
promotes BACE1 ubiquitination and proteasome degradation. PGC-1a stimulates BACE1 metabolism through the enhancement of Fbx2 gene/protein expression
and reduces Aβ production. AD, Alzheimer’s disease; APP, amyloid precursor protein (Adapted from Gong et al., 2010; Aging Cell).
Frontiers in Molecular Neuroscience | www.frontiersin.org 10 January 2016 | Volume 9 | Article 4
Gong et al. UPS in AD and SCI
after SCI in mice (Kobayashi et al., 2010). There is evidence
that in APP overexpressing mice (TgCRND8 mice), there were
increased levels of Aβ at the synaptic terminal and extracellular
accumulation of Aβ, which were predominately located in the
gray matter of the dorsal horn and the central part of dorsal
column of the spinal cord. The enhanced Aβ accumulation
coincides with loss motor neurons (Xie et al., 2000). In ALS
patients, it has been found that Aβ co-localized with oxidative
damage markers such as heme oxygenase-1, and nitro-tyrosine
in abnormal neurons and an increased cleaved caspase-3
immunoreactivity in motor neurons (Calingasan et al., 2005).
BACE1 is an aspartyl protease of the pepsin family that is
mainly expressed in neuronal late Golgi and trans-Golgi (TGN)
compartments as well as the cytoplasmic membrane (Vassar
et al., 1999; Yan et al., 2001). Since BACE1 is an essential
enzyme for Aβ generation as described above, in the past decade,
many compounds have been developed to block BACE1 activity.
Immunostaining showed that BACE1, APP, and Aβ are closely
co-localized with large motor neurons in the ventral horn of
the spinal cord in AD mouse models and that Aβ plaques are
largely derived from the dystrophic presynaptic axonal terminals
originating from glutamatergic neurons arising in the brain and
projecting to spinal cord neurons (Li et al., 2013). Moderate
inhibition of BACE1 activity reduces Aβ production, enhances
clearance of myelin debris and improves axonal regeneration
after SCI (Farah et al., 2011). However, completely abolishing
BACE1 by knocking out the BACE1 gene has adverse effects on
recovery after SCI such as delayed myelination and decreased
myelin thickness (hypomyelination) due to a dysregulation of
neuregulin-1 type III, an EGF-like growth factor (Hu et al.,
2006; Willem et al., 2006). Moreover, animal studies have
shown that complete inhibition of BACE1 activity results in an
elimination of Aβ in neurons, but Aβ is required for certain
physiological neuronal functions such as regulation of neuron-
glia signaling by enhancing spontaneous astrocyte calcium
transient signaling via α7-nAChRs (Lee et al., 2014), activation
of M2 microglia cells after SCI promoting plasticity, axonal
outgrowth and inhibition of inflammation (Kigerl et al., 2009;
Pajoohesh-Ganji and Byrnes, 2011). Since both accumulation
and complete elimination of BACE1/Aβ adversely affect recovery
after SCI, biological regulation of Aβ or BACE1 levels after SCI by
modulation of components of the UPS such as Fbx2-Uch-L1 via
peroxisome proliferator-activated receptor-gamma co-activator
(PGC)-1alpha or gene expression (Gong et al., 2010, 2013b)
may be a feasible strategy for the SCI treatment and AD
(Figure 3).
In summary, BACE1 plays multiple, critical functions after
SCI. Reducing BACE1 expression prevents the accumulation
of Aβ in neurons after SCI, while completely blocking BACE1
activity may result demyelination of axons in white matter tracts.
Thus future in vivo studies are needed to test when biologically
expression of ubiquitin/Uch-L1 as well as other components of
the UPS could beneficial to the recovery of SCI.
SUMMARY
Multiple lines of evidence indicate that dysregulation of any
of several components of the UPS, or mutations in genes that
encode them, exacerbate AD progression and are deleterious
to the recovery of function after SCI. It is notable that many
UPS components such as ubiquitin, Uch-L1, Fbox2 and the
proteasome itself are critical determinants of disease severity
in both SCI and AD. There are, however, many questions to
be answered regarding the mechanisms by which these UPS
components contribute to AD progression and facilitate or
impede recovery of function after SCI. Finally, ubiquitin, Uch-L1,
and the proteasome can be manipulated pharmacologically
providing convenient methods for research applications and
suggesting the possibility that further efforts in this field should
include investigation of the potential utility of drugs that target
these molecules. The major obstacle in developing such therapies
will be the ubiquitous presence of the UPS in eukaryotes which
may require nanomedicine approaches or other tissue-targeting
strategies to minimize adverse effects of such therapies.
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